Literature DB >> 22853857

Lack of interleukin-1 signaling results in perturbed early vein graft wall adaptations.

Peng Yu1, Binh T Nguyen, Ming Tao, Tianyu Jiang, Christine R Mauro, Yuqi Wang, C Keith Ozaki.   

Abstract

BACKGROUND: Vein grafts fail as the result of wall maladaptations to surgical injury and hemodynamic perturbations. Interleukin-1 signaling has emerged as an important mediator of the vascular response to trauma and hemodynamically induced vascular lesions. We therefore hypothesized that interleukin-1 signaling drives early vein graft wall adaptations.
METHODS: Using interleukin-1 type I receptor knockout (IL-1RI(-/-)) and wild-type (B6129SF2/J) mice, we investigated morphologic changes 28 days after interposition isograft from donor inferior vena cava to recipient carotid artery, without (n = 19) or with (n = 13) outflow restriction. The impact of mouse strain on the response to vein arterialization also was evaluated between B6129SF2/J (n = 18) and C57BL/6J (n = 19) mice.
RESULTS: No differences were observed in the traditional end points of intimal thickness and calculated luminal area, yet media+adventitia thickness of the vein graft wall of IL-1RI(-/-) mice was 44% to 52% less than wild-type mice, at the both proximal (P < .01, P < .01) and distal (P = .054, P < .01) portions of vein grafts, for both normal flow and low flow, respectively. Compared with the C57BL/6J strain, B6129SF2/J mice exhibited no difference in vein graft intimal thickness but 2-fold greater media+adventitia thickness (P < .01).
CONCLUSION: When lacking IL-1 signaling, the vein graft wall adapts differently compared with the injured artery, showing typical intima hyperplasia although attenuated media+adventitia thickening. B6129SF2/J mice exhibit more media+adventitia response than C57BL/6J mice. The inflammatory networks that underlie the vein response to arterialization hold many roles in the adaptation of the total wall; thus, the utility of anti-inflammatory approaches to extend the durability of vein grafts comes into question.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22853857      PMCID: PMC3488356          DOI: 10.1016/j.surg.2012.06.005

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  36 in total

1.  Wall shear modulation of cytokines in early vein grafts.

Authors:  Zhihua Jiang; Scott A Berceli; Chun L Pfahnl; Lizhen Wu; Darin Goldman; Ming Tao; Motoko Kagayama; Akihiro Matsukawa; C Keith Ozaki
Journal:  J Vasc Surg       Date:  2004-08       Impact factor: 4.268

2.  Wound healing around and within saphenous vein bypass grafts.

Authors:  J E O'Brien; Y Shi; A Fard; T Bauer; A Zalewski; J D Mannion
Journal:  J Thorac Cardiovasc Surg       Date:  1997-07       Impact factor: 5.209

3.  Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice.

Authors:  Janet Chamberlain; David Evans; Andrea King; Rachael Dewberry; Steven Dower; David Crossman; Sheila Francis
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

4.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Authors:  John H Alexander; Gail Hafley; Robert A Harrington; Eric D Peterson; T Bruce Ferguson; Todd J Lorenz; Abhinav Goyal; Michael Gibson; Michael J Mack; Daniel Gennevois; Robert M Califf; Nicholas T Kouchoukos
Journal:  JAMA       Date:  2005-11-16       Impact factor: 56.272

5.  Strain-dependent vascular remodeling phenotypes in inbred mice.

Authors:  K J Harmon; L L Couper; V Lindner
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

6.  Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow.

Authors:  A Kumar; V Lindner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

7.  Diseased vein grafts express elevated inflammatory cytokine levels compared with atherosclerotic coronary arteries.

Authors:  Jan Felix Christiansen; Dirk Hartwig; J F Matthias Bechtel; Harald Klüter; Hans- H Sievers; Uwe Schönbeck; Claus Bartels
Journal:  Ann Thorac Surg       Date:  2004-05       Impact factor: 4.330

8.  Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury.

Authors:  Kikuo Isoda; Masaru Shiigai; Norio Ishigami; Taizo Matsuki; Reiko Horai; Kenichirou Nishikawa; Masatoshi Kusuhara; Yasuhiro Nishida; Yoichiro Iwakura; Fumitaka Ohsuzu
Journal:  Circulation       Date:  2003-07-21       Impact factor: 29.690

9.  Strain-dependent vascular remodeling: the "Glagov phenomenon" is genetically determined.

Authors:  Vyacheslav A Korshunov; Bradford C Berk
Journal:  Circulation       Date:  2004-06-28       Impact factor: 29.690

10.  Impact of IL-1beta on flow-induced outward arterial remodeling.

Authors:  Zhihua Jiang; Scott A Berceli; Chun L Pfahnl; Lizhen Wu; Chris D Killingsworth; Fernando G Vieira; C Keith Ozaki
Journal:  Surgery       Date:  2004-08       Impact factor: 3.982

View more
  4 in total

1.  Diet-induced obesity drives negative mouse vein graft wall remodeling.

Authors:  Peng Yu; Binh T Nguyen; Ming Tao; Tianyu Jiang; C Keith Ozaki
Journal:  J Vasc Surg       Date:  2013-07-19       Impact factor: 4.268

2.  Distinct subsets of T cells and macrophages impact venous remodeling during arteriovenous fistula maturation.

Authors:  Yutaka Matsubara; Gathe Kiwan; Arash Fereydooni; John Langford; Alan Dardik
Journal:  JVS Vasc Sci       Date:  2020-09-01

Review 3.  Inflammation in Vein Graft Disease.

Authors:  Margreet R de Vries; Paul H A Quax
Journal:  Front Cardiovasc Med       Date:  2018-01-24

4.  Activation of Interleukin-1 Beta in Arterialized Vein Grafts and the Influence of the -511C/T IL-1β Gene Polymorphism.

Authors:  Ayumi Aurea Miyakawa; Thaiz Ferraz Borin; Luciene Cristina Gastalho Campos; Thais Girão-Silva; Joao Carlos Ribeiro-Silva; Luis Alberto Oliveira Dallan; Jose Eduardo Krieger
Journal:  J Cardiovasc Dev Dis       Date:  2019-04-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.